We elected to use nab-PXL in this assay because this drug is a potent activator of TLR4 as shown here (S3 Table) and reported previously [46], and because it mediates recruitment of myeloid cells to human tumors [47] and demonstrates pro-lymphangiogenic activity in mouse tumor models [38], both of which are highly relevant to cancer patients undergoing taxane treatment. The gene discussed is TLR4; the disease is cancer.